Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Liabilities (2016 - 2026)

Summit Therapeutics filings provide 13 years of Total Liabilities readings, the most recent being $101.9 million for Q1 2026.

  • Quarterly Total Liabilities rose 158.09% to $101.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $101.9 million through Mar 2026, up 158.09% year-over-year, with the annual reading at $92.3 million for FY2025, 97.22% up from the prior year.
  • Total Liabilities hit $101.9 million in Q1 2026 for Summit Therapeutics, up from $92.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $537.5 million in Q4 2022 and bottomed at $22.1 million in Q3 2022.
  • Average Total Liabilities over 5 years is $111.7 million, with a median of $92.3 million recorded in 2025.
  • The largest annual shift saw Total Liabilities skyrocketed 1686.35% in 2022 before it crashed 76.7% in 2023.
  • Summit Therapeutics' Total Liabilities stood at $537.5 million in 2022, then crashed by 76.7% to $125.3 million in 2023, then plummeted by 62.63% to $46.8 million in 2024, then skyrocketed by 97.22% to $92.3 million in 2025, then grew by 10.4% to $101.9 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Total Liabilities are $101.9 million (Q1 2026), $92.3 million (Q4 2025), and $69.5 million (Q3 2025).